Scientists Target NAD+ to Slow Aging, Alzheimer's
SkimNews Take
Framing Alzheimer's and Parkinson's as outcomes of NAD+ depletion shifts neurodegenerative treatment from disease-specific to mechanism-specific, potentially broadening intervention targets but also collapsing distinct pathologies into a single metabolic fix that human trials haven't yet validated.
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Scientists from the University of Oslo, Akershus University Hospital, and institutions including Harvard Medical School, the Buck Institute, and Chiba University published a consensus review in Nature Aging focused on NAD+ and its role in aging.
- NAD+ acts as a cellular "fuel regulator" for energy production, DNA repair, and cell function, but its levels naturally decline with age — a drop linked to memory loss, reduced muscle strength, and higher risk of age-related diseases.
- Lead author Dr. Jianying Zhang said fine-tuning NAD+ metabolism holds promise for delaying age-related health decline and premature aging diseases, but warned that proper doses, long-term safety, and individual response variability remain unresolved.
- NR and NMN supplements, vitamin-like compounds that raise NAD+ levels, have shown early trial results including improvements in memory, physical movement, and metabolic health, though the review stresses larger and longer patient studies are needed.
- Clinical trials are underway worldwide, including in Norway, to test NAD+ precursors, while the compounds have fueled a rapidly expanding global supplement market — creating debate over efficacy and whether animal-study results will translate to humans.
- Senior author Dr. Evandro Fei Fang-Stavem said the review consolidates scattered evidence into a "scientific roadmap" to guide both ongoing research and future clinical use of NAD+-based interventions.
- Co-author Prof. Torbjørn Omland said the paper fills a knowledge gap for basic researchers and clinicians, and will inform ongoing NAD+ trials across neurological and cardiovascular conditions.
Why it matters: The review brings together 25+ experts to set a shared research agenda for NAD+ therapies, at a moment when unproven NR and NMN supplements are already a booming global market. Consumers spending money on these products may be getting ahead of the evidence — the scientists themselves explicitly say the right doses, long-term safety, and human translation from animal data remain open questions.
Ask SkimNews
